New Data on the Use of Investigational Agent Belatacept in Kidney Transplant Recipients to Be Presented at 2010 American T

Eight Presentations Featured, Including Two-Year Phase 3 Data

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of eight clinical presentations related to kidney transplantation at the American Transplant Congress, being held May 1 – 5 in San Diego. Belatacept, which received a positive U.S. Food and Drug Administration (FDA) advisory committee vote on March 1 of this year, is currently under FDA review for the prophylaxis of organ rejection in adult kidney transplant recipients. In total, 17 abstracts from company-sponsored studies will be presented during the congress.

“Our clinical development program for belatacept in kidney transplant recipients demonstrates our ongoing commitment to developing targeted biologic therapies for patients with serious disease,” said Brian Daniels, M.D., senior vice president, Global Development and Medical Affairs, Bristol-Myers Squibb. “This year’s congress marks the first presentation of two-year Phase 3 data for belatacept, adding to our ongoing research efforts to better understand how this investigational compound may help kidney transplant recipients."

The eight belatacept clinical presentations related to kidney transplantation are as follows:

         
Session Information   Presentation Title   Lead Author
May 2, 2010

4:00 p.m.

Ballroom 20D

Oral Presentation

 

Belatacept vs Cyclosporine in

Kidney Transplant Recipients:

Two-Year Outcomes from the

BENEFIT Study

  C. Larsen

Emory University

Atlanta, GA

May 2, 2010

4:12 p.m.

Ballroom 20D

Oral Presentation

 

Belatacept vs Cyclosporine in

ECD Kidney Transplants:

Two-Year Outcomes from the

BENEFIT-EXT Study

  A. Durrbach

Bicêtre Hospital, Kremlin Bicêtre, France

May 2, 2010

4:24 p.m.

Ballroom 20D

Oral Presentation

 

Safety Profile of Belatacept in

Kidney Transplant Recipients

from a Pooled Analysis of

Phase 2 and Phase 3 Studies

  J. Grinyó

University Hospital of Bellvitge

Barcelona, Spain

May 3, 2010

8:30 a.m.

Hall F

Oral Presentation

 

Switch from a CNI- to a

Belatacept-Based

Immunosuppressive Regimen

in Kidney Transplant

Recipients Is Safe and Results

in Better Renal Function: 12

Month Results from a Phase II

Study

  L. Rostaing

University Hospital

Toulouse, France

May 3, 2010

5:30 p.m - 6:30 p.m.

Exhibit Hall E

Poster Presentation

 

Belatacept Population

Pharmacokinetics in Renal

Transplant Patients

  Z. Zhou

Bristol-Myers Squibb

Princeton, NJ

May 3, 2010

5:30 p.m. - 6:30 p.m.

Exhibit Hall E

Poster Presentation

 

Pharmacokinetics of

Mycophenolic Acid (MPA)

with Belatacept- or

Cyclosporine (CsA)-Based

Regimens

  L. Rostaing

University Hospital

Toulouse, France

May 4, 2010

2:15 p.m.

Ballroom 20D

Oral Presentation

 

Immunosuppression with

Belatacept-Based, CNI-

Avoiding and Steroid-

Avoiding Regimens vs a

Tacrolimus-Based, Steroid-

Avoiding Regimen in Kidney

Transplant Patients: Results of

a 1-Year, Randomized Study

  R. Ferguson

Ohio State University College of Medicine

Columbus, OH

May 4, 2010

2:27 p.m.
Ballroom 20D

Oral Presentation

 

Outcomes as a Function of

Donor Criteria from a Phase III

Study of Belatacept vs

Cyclosporine in Kidney

Transplantation (BENEFIT-EXT)

  S. Florman

Mount Sinai Medical Center

New York, NY

   

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.



CONTACT:

Bristol-Myers Squibb Company
Media:
Laura Hortas, 609-252-4587
[email protected]
or
Phil McNamara, 609-252-6022
[email protected]
Or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  California  New Jersey

INDUSTRY KEYWORDS:   Surgery  Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.